REXAHN PHARMACEUTICALS, INC.

Form SC 13G/A January 17, 2017

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

Rexahn Pharmaceuticals, Inc. (Name of Issuer)

Common Stock, \$0.0001 par value (Title of Class of Securities)

761640101 (CUSIP Number)

December 31, 2016 (Date of event which requires filing of this statement)

Check the appropriate box to designate the rule pursuant to

which this	
Schedule 13G is	
filed:	
" Rule 13d-1(b)	
x Rule 13d-1(c)	
" Rule 13d-1(d)	
(Page 1 of 6	
Pages)	

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

^{*}The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

CUSIP No. 761640101 13GPage 2 of 6 Pages

NAMES OF

		RTING	
	PERS		
1			
	Empe	ry Asset	
	Manag	gement, LP	
	CHEC	CK	
	THE		
		OPRI(A)TE	
2	BOX		
		BER (b) "	
	OF A	· -	
2	GROU		
3	SEC USE ONLY		
	CITIZENSHIP OR PLACE OF		
4			
4	ORGA	ANIZATION	
	Delaw	, o m o	
NUMBER OF	Delaw		
SHARES		SOLE VOTING	
BENEFICIALLY	5	POWER	
OWNED BY	5	POWER	
EACH			
REPORTING		SHARED	
PERSON WITH		VOTING	
TERSON WITH		POWER	
		TOWER	
		12,500,000	
	6	shares of	
		Common Stock	
		issuable upon	
		exercise of	
		Warrants (See	
		Item 4)*	
		SOLE	
		DISPOSITIVE	
	7	POWER	
	8	SHARED	
		VOTING	
		POWER	
		12 500 000	
		12,500,000	
		shares of	
		Common Stock	
		issuable upon	

exercise of Warrants (See Item 4)*

AGGREGATE

AMOUNT

BENEFICIALLY OWNED BY EACH

REPORTING

PERSON 9

> 12,500,000 shares of Common Stock issuable upon exercise of Warrants (See Item

4)*

CHECK BOX

IF THE

AGGREGATE AMOUNT IN ..

10 ROW (9)

11

12

EXCLUDES CERTAIN SHARES PERCENT OF

CLASS

REPRESENTED BY AMOUNT IN ROW

(9)

4.99% (See Item 4)*

TYPE OF REPORTING **PERSON**

PN

^{*} As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) gives effect to such blocker. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blocker, is less than the number of securities reported in rows (6), (8) and (9).

CUSIP No. 761640101 13GPage 3 of 6 Pages

1	NAMES OF REPORTING PERSONS	
	Ryan M. Lane	
	CHECK	
	THE	
_	APPROPRIATE	
2	BOX IF A	
	MEMBER (b) "	
	OF A	
_	GROUP	
3	SEC USE ONLY	
	CITIZENSHIP OR	
	PLACE OF ORGANIZATION	
4		
	United States	
NUMBER OF	SOLE	
SHARES	VOTING	
BENEFICIALLY	5 POWER	
OWNED BY		
EACH		
REPORTING	SHARED	
PERSON WITH	VOTING	
	POWER	
	12,500,000	
	12,200,000	

6 shares of
Common Stock
issuable upon
exercise of
Warrants (See
Item 4)*

SOLE

DISPOSITIVE

7 POWER

8 SHARED DISPOSITIVE POWER

> 12,500,000 shares of Common Stock issuable upon exercise of

Warrants (See

Item 4)*

AGGREGATE

AMOUNT

BENEFICIALLY

OWNED BY EACH

REPORTING

9 PERSON

12,500,000 shares of

Common Stock

issuable upon exercise

of Warrants (See Item

4)*

CHECK BOX

IF THE

AGGREGATE

AMOUNT IN ...

ROW (9)

10

EXCLUDES

LACLUDES

CERTAIN

SHARES

PERCENT OF

CLASS

REPRESENTED BY

11 AMOUNT IN ROW

(9)

4.99% (See Item 4)*

TYPE OF

REPORTING

12 PERSON

IN

^{*} As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) gives effect to such blocker. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blocker, is less than the number of securities reported in rows (6), (8) and (9).

CUSIP No. 761640101 13GPage 4 of 6 Pages

NAMES OF

	IALIVI	LS OI	
	REPORTING		
1	PERSONS		
	Martin D. Hoe		
	CHECK		
	THE		
	APPROPRI ATE		
2	BOX IF A		
	MEMBER (b) "		
	OF A		
	GROU	JP	
3	SEC USE ONLY		
	CITIZ	ENSHIP OR	
	PLACE OF		
4	ORGANIZATION		
	United States		
NUMBER OF		SOLE	
SHARES		VOTING	
BENEFICIALLY	5	POWER	
OWNED BY			
EACH			
REPORTING		SHARED	
PERSON WITH		VOTING	
		POWER	
		12 500 000	
	_	12,500,000	
	6	shares of	
		Common Stock	
		issuable upon	

7

8 SHARED DISPOSITIVE POWER

POWER

exercise of Warrants (See Item 4)* SOLE

DISPOSITIVE

12,500,000 shares of Common Stock issuable upon exercise of

Warrants (See

Item 4)*

AGGREGATE

AMOUNT

BENEFICIALLY

OWNED BY EACH

REPORTING

PERSON

9

10

12,500,000 shares of

Common Stock

issuable upon exercise

of Warrants (See Item

4)*

CHECK BOX

IF THE

AGGREGATE

AMOUNT IN ...

ROW (9)

EXCLUDES

CERTAIN

SHARES

PERCENT OF

CLASS

REPRESENTED BY

11 AMOUNT IN ROW

(9)

4.99% (See Item 4)*

TYPE OF

REPORTING

12 PERSON

IN

^{*} As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) gives effect to such blocker. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blocker, is less than the number of securities reported in rows (6), (8) and (9).

CUSIP No. 761640101 13GPage 5 of 6 Pages

This Amendment No. 2 (this "Amendment") amends the statement on Schedule 13G filed on November 10, 2015 (the "Original Schedule 13G" as amended by Amendment No. 1 to the Original Schedule 13G filed on January 19, 2016, the Original Schedule 13G, as amended, the "Schedule 13G"), with respect to shares of Common Stock, \$0.0001 par value (the "Common Shares"), of Rexahn Pharmaceuticals, Inc. (the "Company"). Capitalized terms used herein and not otherwise defined in this Amendment have the meanings set forth in the Schedule 13G. This Amendment amends and restates Items 4 and 5 in their entirety as set forth below.

Item 4. OWNERSHIP.

The information as of the date of the event which requires filing of this statement required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 237,368,785 shares of Common Stock issued and outstanding as of November 4, 2016, as represented in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 4, 2016, and the exercise of the reported warrants (the "Reported Warrants") subject to the Blocker (as defined below).

Pursuant to the terms of the Reported Warrants, the Reporting Persons cannot exercise the Reported Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 4.99% of the outstanding shares of Common Stock (the <u>Blocker</u>"), and the percentage set forth in Row 11 of the cover page for each Reporting Person gives effect to the Blocker. Consequently, as of the date of the event which requires filing of this statement, the Reporting Persons were not able to exercise all of the Reported Warrants due to the Blocker.

The Investment Manager, which serves as the investment manager to the Empery Funds, may be deemed to be the beneficial owner of all shares of Common Stock held by, and underlying the Reported Warrants (subject to the Blocker) held by, the Empery Funds. Each of the Reporting Individuals, as Managing Members of the General Partner of the Investment Manager with the power to exercise investment discretion, may be deemed to be the beneficial owner of all shares of Common Stock held by, and underlying the Reported Warrants (subject to the Blocker) held by, the Empery Funds. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of shares of Common Stock owned by another Reporting Person. Each of the Empery Funds and the Reporting Individuals hereby disclaims any beneficial ownership of any such shares of Common Stock.

Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [X]

CUSIP No. 761640101 13GPage 6 of 6 Pages

SIGNATURES

After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

DATED: January 17, 2017

EMPERY ASSET MANAGEMENT, LP By: EMPERY AM GP, LLC, its General Partner

By: <u>/s/ Ryan M. Lane</u>
Name: Ryan M. Lane
Title: Managing Member

/s/ Ryan M. Lane Ryan M. Lane

/s/ Martin D. Hoe

Martin D. Hoe